MiNK Therapeutics (INKT) Projected to Release Quarterly Earnings on Thursday

MiNK Therapeutics (NASDAQ:INKT) is expected to be announcing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect MiNK Therapeutics to announce earnings of ($0.60) per share for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:30 AM ET.

MiNK Therapeutics (NASDAQ:INKT) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.20. On average, analysts expect MiNK Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

MiNK Therapeutics Stock Performance

NASDAQ:INKT opened at $10.95 on Tuesday. The stock has a 50-day simple moving average of $11.42 and a 200 day simple moving average of $11.25. MiNK Therapeutics has a one year low of $8.48 and a one year high of $18.17. The company has a market capitalization of $54.53 million, a price-to-earnings ratio of -3.86 and a beta of 0.48.

Hedge Funds Weigh In On MiNK Therapeutics

An institutional investor recently bought a new stake in MiNK Therapeutics stock. DRW Securities LLC purchased a new position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned approximately 0.55% of MiNK Therapeutics as of its most recent filing with the SEC. 2.87% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently issued reports on INKT shares. HC Wainwright reissued a “buy” rating and issued a $35.00 price target on shares of MiNK Therapeutics in a report on Monday, May 18th. Zacks Research upgraded shares of MiNK Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 14th. Wall Street Zen raised MiNK Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Weiss Ratings upgraded MiNK Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.00.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.